Cargando…

Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity

LAYMAN SUMMARY: HER2 is an oncogenic driver in a subset of breast cancer. Despite the fact that there are the options of several anti-HER2 targeted therapies, most patients with metastatic HER2+ breast cancer die from the disease. Therapies to overcome treatment resistance in the metastatic settings...

Descripción completa

Detalles Bibliográficos
Autores principales:	Koirala, Nischal, Dey, Nandini, Aske, Jennifer, De, Pradip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9224522/ https://www.ncbi.nlm.nih.gov/pubmed/35742993 http://dx.doi.org/10.3390/ijms23126547

Ejemplares similares

Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR
por: Dey, Nandini, et al.
Publicado: (2021)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Patient-Derived Primary Cancer-Associated Fibroblasts Mediate Resistance to Anti-Angiogenic Drug in Ovarian Cancers
por: Sulaiman, Raed, et al.
Publicado: (2023)

Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers
por: Sulaiman, Raed, et al.
Publicado: (2023)

Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance
por: De, Pradip, et al.
Publicado: (2022)

Cancer-Associated Fibroblast Functions as a Road-Block in Cancer Therapy
por: De, Pradip, et al.
Publicado: (2021)

Cancer-Associated Fibroblasts in Conversation with Tumor Cells in Endometrial Cancers: A Partner in Crime
por: Pradip, De, et al.
Publicado: (2021)

RAC1 Takes the Lead in Solid Tumors
por: De, Pradip, et al.
Publicado: (2019)

Mutation-Driven Signals of ARID1A and PI3K Pathways in Ovarian Carcinomas: Alteration Is An Opportunity
por: De, Pradip, et al.
Publicado: (2019)

Active RAC1 Promotes Tumorigenic Phenotypes and Therapy Resistance in Solid Tumors
por: De, Pradip, et al.
Publicado: (2020)

A Laboratory-Friendly CTC Identification: Comparable Double-Immunocytochemistry with Triple-Immunofluorescence
por: Sulaiman, Raed, et al.
Publicado: (2022)

Percutaneous-Reinforced Osteoplasty: A Review of Emerging Treatment Strategies for Bone Interventions
por: Koirala, Nischal, et al.
Publicado: (2022)

Emerging Targeted Therapies for HER2-Positive Breast Cancer
por: Mercogliano, María Florencia, et al.
Publicado: (2023)

Triple Fluorescence staining to Evaluate Mechanism-based Apoptosis following Chemotherapeutic and Targeted Anti-cancer Drugs in Live Tumor Cells
por: De, Pradip, et al.
Publicado: (2018)

Wnt-beta-catenin pathway signals metastasis-associated tumor cell phenotypes in triple negative breast cancers
por: De, Pradip, et al.
Publicado: (2016)

A CAF-Based Two-Cell Hybrid Co-Culture Model to Test Drug Resistance in Endometrial Cancers
por: Sulaiman, Raed, et al.
Publicado: (2023)

Precision Medicine in Solid Tumors: How Far We Traveled So Far?
por: Dey, Nandini, et al.
Publicado: (2022)

Oncogenic nexus of cancerous inhibitor of protein phosphatase 2A (CIP2A): An oncoprotein with many hands
por: De, Pradip, et al.
Publicado: (2014)

RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers
por: De, Pradip, et al.
Publicado: (2016)

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer
por: Hong, Joohyun, et al.
Publicado: (2022)

HER-2-Targeted Nanoparticles for Breast Cancer Diagnosis and Treatment
por: Sitia, Leopoldo, et al.
Publicado: (2022)

Characterization and Clinical Relevance of Endometrial CAFs: Correlation between Post-Surgery Event and Resistance to Drugs
por: Sulaiman, Raed, et al.
Publicado: (2023)

Target HER four in breast cancer?
por: Brockhoff, Gero
Publicado: (2019)

Steroid Hormone Receptors: Links With Cell Cycle Machinery and Breast Cancer Progression
por: Saha, Suryendu, et al.
Publicado: (2021)

Identification and Morphological Characterization of Features of Circulating Cancer-Associated Macrophage-like Cells (CAMLs) in Endometrial Cancers
por: Sulaiman, Raed, et al.
Publicado: (2022)

Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib
por: Kourie, Hampig Raphael, et al.
Publicado: (2017)

Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs
por: Willis, Scooter, et al.
Publicado: (2015)

SNHG6 203 RNA May be Involved in the Cell Cycle Progression in HER2-Negative Breast Cancer Cells
por: Jafari-Oliayi, Amin, et al.
Publicado: (2022)

Role of HER2-Targeted Agents in Adjuvant Treatment for Breast Cancer
por: Mukohara, Toru
Publicado: (2011)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Trastuzumab resistance in HER2-positive breast cancer: Mechanisms, emerging biomarkers and targeting agents
por: Wang, Zhen-hao, et al.
Publicado: (2022)

The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment
por: Lin, Mengmeng, et al.
Publicado: (2022)

LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression
por: Montañez-Wiscovich, ME, et al.
Publicado: (2009)

Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors
por: Floros, Konstantinos V., et al.
Publicado: (2021)

Differential Activation of Wnt-β-Catenin Pathway in Triple Negative Breast Cancer Increases MMP7 in a PTEN Dependent Manner
por: Dey, Nandini, et al.
Publicado: (2013)

Cardiovascular Toxicity of Novel HER2-Targeted Therapies in the Treatment of Breast Cancer
por: Dent, Susan F., et al.
Publicado: (2021)

Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm
por: Yang, Charlie, et al.
Publicado: (2023)

The role of neoadjuvant her2-targeted therapies in her2-overexpressing breast cancers
por: Lemieux, J., et al.
Publicado: (2009)

Mathematical Models for Blood Flow Quantification in Dialysis Access Using Angiography: A Comparative Study
por: Koirala, Nischal, et al.
Publicado: (2021)

HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development
por: Singh, J C, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_97m7lqpr3ijrbar12b0hurbmll